Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
In CD30 positive, CD20 weak gray zone lymphoma, is first line AVD + Brentuximab or R-BV-CHP better than RCHOP or DA-EPOCH?
Related Questions
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?
How do you approach frontline treatment for an elderly patient with adult T-cell leukemia-lymphoma (ATL)?
How would you treat a tDLBCL originally treated with R-CHOP who relapses with DLBCL 15 years after the original diagnosis?
How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
Is there a role for thiotepa-based auto transplant for consolidation in PCNSL if the patient had progression on both MTX and Ara-C?
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?
How would you treat an elderly male with history of mantle cell lymphoma who relapsed after chemoimmunotherapy and cBTKi w/ multiple co-morbidities including CKD and CHF w/ low EF?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
